Rifaximin in Fatty Liver Disease

NCT01355575 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Primary endpoint data review concluded no further patients required.

Conditions

Nonalcoholic Fatty Liver Disease
NAFLD
Nonalcoholic Steatohepatitis

Interventions

DRUG: Rifaximin

Sponsor

Imperial College London

Collaborators

[object Object]